aod 9604 with tirzepatide Understanding 9604: The Science of the “Fat-Burning” Peptide Fragment AOD- 9604

Targeting and alteration of tight junctions by bacteria and their virulence factors such as Clostridium perfringens enterotoxin

High performance

The clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualised treatment options for people living with obesity. The data presented on Roches obesity assets include: Enicepatide (CT-388) : Late-breaking data from the Phase II (CT388-103) study will highlight clinical weight loss outcomes from investigational enicepatide in people living with overweight/obesity

13%, p = 0.032) 20

While highly praised for ease of use, it generates significant plastic waste and lacks dose flexibility